Register entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 7
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
7| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 7897792 | AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)avutometinib potassium; defactinib hydrochloride | substance, product | Feb 2027 |
| 8247411 | AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)avutometinib potassium; defactinib hydrochloride | substance, product | Apr 2028 |
| 7928109 | AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)avutometinib potassium; defactinib hydrochloride | substance, product | Aug 2029 |
| 11400090 | AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)avutometinib potassium; defactinib hydrochloride | use | Oct 2038 |
| 11517573 | AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)avutometinib potassium; defactinib hydrochloride | use | Sept 2040 |
| 11873296 | AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)avutometinib potassium; defactinib hydrochloride | product | Dec 2042 |
| 12509450 | AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)avutometinib potassium; defactinib hydrochloride | product | Dec 2042 |
| Product | Exclusivity | Until |
|---|---|---|
| AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE | ODE-525 Orphan drug | May 2032 |
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| AVMAPKI FAKZYNJA CO-PACK | avutometinib potassium and defactinib hydrochloride | kit | 71779-623NDA |
Enquiry
Common questions
- Is Verastem Inc. FDA approved?
- Verastem Inc. holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Verastem Inc. make?
- 1 product is listed under Verastem Inc. in the openFDA NDC Directory, most often as kit. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.